Boehringer Ingelheim offers interchangeable biosimilar to Humira
Boehringer Ingelheim’s Adalimumab-adbm injection, the company’s interchangeable biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost. Adalimumab-adbm is approved to treat multiple chronic inflammatory diseases and will be priced at an 81% discount to Humira. It also is available under the brand name Cyltezo, which launched in July 2023 and is priced at a 5% discount to Humira.
“We understand that finding affordable medications is a persistent challenge for many, which is why we strive to ensure our products are widely accessible,” said Stephen Pagnotta, executive director and Biosimilar Commercial Lead at Boehringer Ingelheim.
[Read more: 7 companies are rolling out Humira biosimilars]
Pagnotta added, “Biosimilars are intended to contribute to the economic sustainability of healthcare systems, and it is our hope that this dual pricing approach will contribute to that sustainability, improve access to Adalimumab-adbm and help meet the varied needs of people with a variety of chronic inflammatory diseases.”
Adalimumab-adbm is interchangeable to Humira and is a citrate-free formulation, available as 40 mg/0.8 ml, 20 mg/0.4 ml and 10 mg/0.2 ml pre-filled syringes and as a 40 mg/0.8 ml pre-filled autoinjector.